<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Tue, 19 May 2026 23:56:19 -0400--><rss version="2.0">
    <channel>
        <title>Rigel Pharmaceuticals, Inc. (RIGL) Press Releases</title>
        <link>https://www.rigel.com/news-media/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/rigel/files/rigel-logo-color-R_%281%29.png</url>
                <title>Rigel Pharmaceuticals, Inc. Logo</title>
                <link>https://www.rigel.com</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/438/rigel-to-present-at-the-2026-rbc-capital-markets-global</link>
                <pubDate>Thu, 14 May 26 08:05:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/438/rigel-to-present-at-the-2026-rbc-capital-markets-global</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/437/rigel-enters-exclusive-global-licensing-agreement-for</link>
                <pubDate>Tue, 12 May 26 07:00:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/437/rigel-enters-exclusive-global-licensing-agreement-for</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Reports First Quarter 2026 Financial Results]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/436/rigel-reports-first-quarter-2026-financial-results</link>
                <pubDate>Tue, 05 May 26 16:01:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/436/rigel-reports-first-quarter-2026-financial-results</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/435/rigel-announces-conference-call-and-webcast-to-report-first</link>
                <pubDate>Tue, 28 Apr 26 08:05:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/435/rigel-announces-conference-call-and-webcast-to-report-first</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial</link>
                <pubDate>Tue, 31 Mar 26 08:05:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/433/rigel-provides-fourth-quarter-and-full-year-2025-financial</link>
                <pubDate>Tue, 03 Mar 26 16:01:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/433/rigel-provides-fourth-quarter-and-full-year-2025-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/432/rigel-announces-conference-call-and-webcast-to-report</link>
                <pubDate>Tue, 24 Feb 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/432/rigel-announces-conference-call-and-webcast-to-report</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Appoints Michael P. Miller to the Board of Directors]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/431/rigel-appoints-michael-p-miller-to-the-board-of-directors</link>
                <pubDate>Tue, 03 Feb 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/431/rigel-appoints-michael-p-miller-to-the-board-of-directors</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Provides Business Update and 2026 Outlook]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/430/rigel-provides-business-update-and-2026-outlook</link>
                <pubDate>Mon, 12 Jan 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/430/rigel-provides-business-update-and-2026-outlook</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/428/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare</link>
                <pubDate>Wed, 07 Jan 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/428/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare</guid>
                                                                            </item>
            </channel>
</rss>